Int J Clin Pharm. 2016 Feb;38(1):70-9. Comparative Study; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov’t
This noninferiority trial compares the effects of IDSA/ATS guideline–recommended vs conventional antibiotic treatment duration on symptom and clinical resolution in hospitalized patients with community-acquired pneumonia.
A dose of 35 mg/kg rifampicin was safe, reduced the time to culture conversion inliquid media, and could be a promising component of future, shorter regimens. Ouradaptive trial design was successfully implemented in a multi-centre, high tuberculosisburden setting, and could speed regimen development at reduced cost.